<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-id journal-id-type="iso-abbrev">Crit Care</journal-id><journal-title-group><journal-title>Critical Care</journal-title></journal-title-group><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4473042</article-id><article-id pub-id-type="publisher-id">cc14571</article-id><article-id pub-id-type="doi">10.1186/cc14571</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Subanesthetic xenon increases erythropoietin levels in humans and remains traceable in the first 24 hours after exposure: a randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" id="A1"><name><surname>Ney</surname><given-names>J</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Stoppe</surname><given-names>C</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Brenke</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Goetzenich</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Kraemer</surname><given-names>S</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Schaelte</surname><given-names>G</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Fahlenkamp</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Rossaint</surname><given-names>R</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Coburn</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>RWTH Aachen University, Aachen, Germany</aff><pub-date pub-type="ppub"><year>2015</year></pub-date><pub-date pub-type="epub"><day>16</day><month>3</month><year>2015</year></pub-date><volume>19</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">35th International Symposium on Intensive Care and Emergency Medicine</named-content><named-content content-type="supplement-sponsor">Pubication charges for this supplement were funded by ISICEM.</named-content></supplement><fpage>P491</fpage><lpage>P491</lpage><permissions><copyright-statement>Copyright &#x000a9; 2015 Ney et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Ney et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://ccforum.com/content/19/S1/P491"/><conference><conf-date>17-20 March 2015</conf-date><conf-name>35th International Symposium on Intensive Care and Emergency Medicine</conf-name><conf-loc>Brussels, Belgium</conf-loc></conference></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>The noble gas xenon was recently amended to the list of prohibited substances by the World Anti-Doping Agency as it is supposed to trigger the production of HIF-1&#x003b1; and subsequently erythropoietin. Subsequently, researchers and clinicians started a scientific discussion about the potential clinical benefit in support of humans exposed to high demand, such as critically ill patients. The objective of this study was therefore to evaluate the effect of xenon on serum levels of erythropoietin in healthy volunteers.</p></sec><sec sec-type="methods"><title>Methods</title><p>This is a monocenter, randomized, blinded, crossover trial, which was registered at <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">http://ClinicalTrials.gov</ext-link> (NCT01285271). Healthy study test persons were spontaneously breathing randomly 1 hour of xenon 30% (Xe/O<sub>2</sub> 30%/65%) or control gas (N<sub>2</sub>/O<sub>2</sub> 30%/65%). The primary outcome parameter was the erythropoietin level 24 hours after exposure. Secondary outcome parameters are xenon's elimination kinetics measured in blood and exhalation samples.</p></sec><sec sec-type="results"><title>Results</title><p>The application of xenon increases erythropoietin levels with a maximum 24 hours after exposure (1.32 (0.99 to 1.66) <italic>P </italic>= 0.033) compared with the baseline values and compared with control values (0.87 (0.68 to 1.05) <italic>P </italic>= 0.012, Figure <xref ref-type="fig" rid="F1">1</xref>). Xenon was gas chromatographically traceable in blood and exhalation probes up to 24 hours after exposure.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p><bold>Erythropoietin levels after 30% xenon exposure</bold>.</p></caption><graphic xlink:href="cc14571-1"/></fig></sec><sec sec-type="conclusions"><title>Conclusion</title><p>One hour of a subanesthetic level of xenon increases erythropoietin levels in healthy study test persons and remains gas chromatographically traceable in blood and exhalation probes 24 hours after exposure. These findings may stimulate larger studies to confirm these Results and to open new avenues for the therapeutic use of xenon in critically ill patients.</p></sec></body></article>